Answer

IFF (Scent) recovery: drivers, H2 evolution (Fine Fragrance vs. Consumer Fragrance), and the R&D plan aimed toward 2027

1) Drivers of Scent’s recovery

Based on management’s commentary, the Scent recovery is being driven by (a) normalization of “Fragrance Ingredients” performance, (b) improved execution and R&D/portfolio rebuilding in Consumer and Fine Fragrance, and (c) active navigation of Middle East-related volatility in Fine Fragrance.

A. “Fragrance Ingredients” momentum is supporting near-term Scent growth, but is expected to normalize

In Q2, Scent delivered 8% sales growth, with double-digit growth in Fragrance Ingredients being a key driver. ¹²
Management attributed Q2 Fragrance Ingredients strength to both year-ago comp effects and strategic leverage of the synthetics portfolio to capture more sales amid macro environment, supply chain disruptions, and higher Brent crude prices. ¹
Going forward, management expects Fragrance Ingredients to normalize, with growth shifting back toward higher value-added ingredients versus traditional synthetics; they also state this normalization is not expected in the second half of this year, but is expected as they progress into next year and the year after. ³

B. Fine Fragrance recovery is constrained by Middle East volatility but is improving toward Q4

Fine Fragrance grew low single digits, inclusive of the impact of the Middle East conflict. ²
Management said the team “did a very good job at managing the challenges in the Middle East,” with Q2 finishing slightly positive versus an initial expectation of mid-single-digit decline before the quarter began. ¹
For the second half, management guided that Fine Fragrance will be softer in Q3 and stronger in Q4, with mid-single-digit range growth on a second-half basis (and continues on “strong comparables”). ³

C. Consumer Fragrance is rebuilding R&D capability and re-establishing a go-to-market approach to regain market share

Management framed the Consumer Fragrance recovery as a function of rebuilding R&D capability and the go-to-market approach with customers, with an explicit goal of driving market share gains. ³
In Q2, Consumer Fragrance was strong (high single-digit increase in Consumer Fragrance), but management expects it to normalize to a low single-digit rate going forward. ³²
This recovery is also tied to R&D progress: management states that 2.5 years ago the R&D pipeline “was not what it should have been,” and that now they have a stronger R&D capability, a great R&D team, leading-edge new Fine and Consumer fragrances and consumer fragrances, and a pipeline of molecules and delivery systems. ⁴

2) How Fine Fragrance and Consumer Fragrance will evolve in 2H (Q3–Q4)

Management’s second-half framework is quantitative (growth-rate ranges) and also qualitative (what is expected to “normalize” or “recover” as comps and volatility change).

Fine Fragrance (Scent): softer in Q3, stronger in Q4; ~mid-single-digit in 2H

Management’s expectation is that Fine Fragrance is a little bit softer in Q3 and stronger in Q4, producing mid-single-digit growth on a second-half basis. ³
They also emphasize that the Middle East-driven uncertainty is being managed, and that they are “factoring in a softer Q3,” partly due to a large year-over-year comp: in Q3 last year Fine Fragrance grew 20%. ¹

Interpretation (from the excerpts): The recovery path is not linear—Q3 is intentionally treated as a volatility/comp-adjusted dip, followed by improvement as Q4 benefits both from comparison dynamics and improved underlying execution. ³¹

Consumer Fragrance (Scent): 2H normalizes to low single digits after a strong Q2; expects “normalization” rather than acceleration

Management put Consumer Fragrance in the low single-digit range for “go-forward,” stating that Q2 was high single-digit and is expected to normalize. ³
Scent’s reported performance in Q2 supports that framing: management indicates Scent was driven by double-digit growth in Fragrance Ingredients and high single-digit increase in Consumer Fragrance, while Fine Fragrance was low single digits inclusive of Middle East impact. ²
They also connect Consumer Fragrance progress to R&D and commercial rebuilding aimed at market share gains. ³

Interpretation (from the excerpts): Consumer Fragrance recovery appears to be more about sustaining momentum through rebuilding (R&D + customer go-to-market) than about a sharp acceleration in 2H; the company expects normalization from the strong Q2 print toward a low-single-digit run-rate. ³²

Important cross-current: Fragrance Ingredients will also normalize (but “not in 2H this year”)

Although the question focuses on Fine Fragrance and Consumer Fragrance, the excerpts also make clear that Scent’s recovery is partly being carried by Fragrance Ingredients and that normalization timing matters:

Management states Fragrance Ingredients is expected to normalize on a go-forward basis, with growth shifting toward higher-value natural products; they explicitly add that this is “not in the second half of this year,” but becomes more relevant as they move into next year and the year after. ³

3) Plan for R&D to support 2027

Management’s R&D plan is described less as a detailed multi-year budget and more as an operational transformation: fixing the pipeline quality, strengthening capabilities, and building a molecule + delivery system pipeline designed to support ongoing competitiveness into the late period (including 2027).

A. R&D capability reset and pipeline rebuilding completed enough to enable “leading-edge” launches

Management says that 2.5 years ago the R&D pipeline “was not what it should have been” and that today they have a very strong R&D capability and great perfumers developing leading-edge new Fine Fragrances and Consumer Fragrances. ⁴
They also state they now have a great pipeline of molecules as well as delivery systems, indicating that both discovery and formulation/technology delivery are being supported. ⁴

B. The R&D plan is explicitly linked to market share gains and evolution beyond 2026 (toward a “strong competitive position”)

Management’s Consumer Fragrance framing ties R&D improvement to rebuilding the go-to-market approach and driving market share gains. ³
On the broader Scent outlook, management says that while certain transitions (including the ingredient mix shift toward higher-value natural products) will take time, “as we go into next year and the year after, we believe we’ll have a really strong competitive position.” ³

How this supports 2027 (grounded in the excerpt timing): Since “next year and the year after” follows the current year context, the excerpts imply that the R&D pipeline strengthening and the associated competitive positioning are intended to translate into stronger competitive outcomes in the later horizon consistent with 2027. ³⁴

C. R&D is treated as a sustained investment loop, not a one-off recovery fix

Management explicitly frames innovation/R&D as important to a strategy cycle where reinvestment supports better growth, margin, and continued reinvestment (discussed in the context of Remainco strategy and innovation). ⁵
They state “innovation matters” and that maintaining R&D investment (with R&D as 8% to 9% of sales) is “really important” to keep setting themselves apart. ⁵

Bottom line

Drivers of recovery: Q2 strength came largely from Fragrance Ingredients outperformance plus solid Consumer Fragrance momentum, while Fine Fragrance was stabilized despite Middle East volatility. ¹²
2H evolution: Fine Fragrance is expected to be softer in Q3 and stronger in Q4, yielding mid-single-digit growth for 2H. ³ Consumer Fragrance is expected to normalize from high-single-digit Q2 to low-single-digit going forward, supported by restored R&D capability and customer-facing go-to-market execution. ³²
R&D plan toward 2027: Management describes a multi-year R&D turnaround—improving pipeline quality, strengthening perfumer capability, and building a robust molecules + delivery systems pipeline—aimed at translating into stronger competitive position in the “next year and the year after,” with innovation treated as an ongoing reinvestment cycle. ³⁴⁵

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF’s Scent Recovery Driven by Fragrance Ingredients, R&D Push Toward 2027 in Q2 2026

Sources used

Research question

Answer

IFF (Scent) recovery: drivers, H2 evolution (Fine Fragrance vs. Consumer Fragrance), and the R&D plan aimed toward 2027

1) Drivers of Scent’s recovery

A. “Fragrance Ingredients” momentum is supporting near-term Scent growth, but is expected to normalize

B. Fine Fragrance recovery is constrained by Middle East volatility but is improving toward Q4

C. Consumer Fragrance is rebuilding R&D capability and re-establishing a go-to-market approach to regain market share

2) How Fine Fragrance and Consumer Fragrance will evolve in 2H (Q3–Q4)

Fine Fragrance (Scent): softer in Q3, stronger in Q4; ~mid-single-digit in 2H

Consumer Fragrance (Scent): 2H normalizes to low single digits after a strong Q2; expects “normalization” rather than acceleration

Important cross-current: Fragrance Ingredients will also normalize (but “not in 2H this year”)

3) Plan for R&D to support 2027

A. R&D capability reset and pipeline rebuilding completed enough to enable “leading-edge” launches

B. The R&D plan is explicitly linked to market share gains and evolution beyond 2026 (toward a “strong competitive position”)

C. R&D is treated as a sustained investment loop, not a one-off recovery fix

Bottom line

References

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

Keep Reading

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

IFF Scent Recovery Gains Momentum in Q2 2026 with Second-Half Outlook

IFF's Scent Recovery Fueled by 2026 Q2 R&D Reboot; H2 Outlook and 2027 Plan

IFF Scent Recovery Driven by Fragrance Ingredients, 2H 2026 Outlook, and 2027 R&D Plan

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Fueled by Fragrance Ingredients, Q2 2026 Outlook, and 2027 R&D Plan

IFF Scent Recovery Strengthens as Q2 2026 Highlights R&D Path to 2027

IFF Scent Recovery Gains Traction in Q2 2026, R&D Plan Sets 2027 Outlook

IFF Scent Recovery Gains Momentum in 2H, R&D Plan Targets 2027

IFF Scent Recovery Driven by Fragrance Ingredients; H2 Outlook and 2027 R&D Plan

IFF's Scent Recovery Fueled by Fragrance Ingredients Momentum and 2027 R&D Plan

IFF Q2 2026 Highlights on Scent Recovery, H2 Fragrance Outlook, and 2027 R&D Plan